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Objectives:  Symptomatic  brain  metastases  (BM)  occur  frequently  after  chemoradiotherapy  (CRT)  for  stage
III NSCLC.  Aim  of  the  current  study  was  to  determine  whether  the  speciﬁc  chemotherapy  used  in  a CRT
regimen  inﬂuences  BM  development.
Materials  and  methods:  Retrospective  multicenter  study  including  all consecutive  stage  III NSCLC  who
completed  CRT.  Primary  endpoints:  symptomatic  BM  development,  whether  this  was  the  only  site of
ﬁrst relapse.  Differences  between  regimens  were  assessed  with  a logistic  regression  model  includ-
ing  known  BM  risk  factors  and  the  speciﬁc  chemotherapy:  concurrent  versus  sequential  (cCRT/sCRT),
within  cCRT:  daily  low  dose cisplatin  (LDC)-cyclic  dose  polychemotherapy;  LDC-(non-)taxane  cyclic  dose;
LDC–polychemotherapy  subgroups  of ≥50 patients.
Results:  Between  January  2006  and  June  2014,  838  patients  were  eligible  (737  cCRT,  101  sCRT).  18.2%
developed  symptomatic  BM, 8.0%  had  BM as  only  site  of  ﬁrst  relapse.  BM patients  were  signiﬁcantly
younger,  female,  had  more  advanced  N-stage  and  had  adenocarcinoma  histology.  In  both  cCRT  and
sCRT  BM  were  found  in  18% (p = 0.904).  In  cyclic  dose  cCRT  (N  =  346)  and  LDC  (N = 391)  BM  were
found in 18.8%  and  17.9%,  respectively  (p  = 0.757).  In 7.2%  and  8.7%, respectively,  BM  were  the  only
site  of  ﬁrst  relapse  (p = 0.463).  The  chemotherapy  used  (cCRT  versus  sCRT)  had  no  inﬂuence  on BM
development,  not  for  all  brain  relapses  nor  as only  site  of  ﬁrst  relapse  (OR  0.88  (p = 0.669),  OR  0.93
(p  =  0.855),  respectively).  LDC  versus  cyclic  dose  cCRT  was not  signiﬁcantly  different:  neither  for  all
brain  relapses  nor  as  only  site  of  ﬁrst  relapse  (OR  0.96 (p = 0.819),  OR 1.21  (p =  0.498),  respectively).
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Comparable  results  were  found  for LDC  versus  cyclic  dose  non-taxane  (N =  277) and cyclic dose  taxane
regimens (N  = 69) and  for  cCRT  regimens  with  ≥50  patients  (LDC  versus  cisplatin/etoposide  (N = 188),
cisplatin/vinorelbin  (N =  65),  weekly  cisplatin/docetaxel  (N  = 60)).
Conclusion:  approximately  18%  developed  symptomatic  BM after  stage  III diagnosis,  not dependent  on
type  of  chemotherapy  regimen  used  within  a CRT  treatment.
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a. Introduction
The standard treatment for most patients with stage III non-
mall cell lung cancer (NSCLC) is combined chemoradiation (CRT).
oncurrent CRT (cCRT) results in a superior overall survival (OS)
ompared to sequential CRT (sCRT) [1]. As brain metastases fre-
uently occur in locally advanced NSCLC it is routine practice to
erform brain imaging during staging [2,3]. The brain is still a
requent site of relapse after CRT, as 13–15% of patients develop
ymptomatic brain metastases within the ﬁrst year after NSCLC
iagnosis [4,5]. Most brain relapses are diagnosed in this ﬁrst year,
ut over 30% occur later [4,5]. Symptomatic brain metastases have
 negative impact on quality of life (QoL) and are associated with a
orse OS [6,7]. Known risk factors for brain metastases are adeno-
arcinoma histology and younger age [4,8]. Several chemotherapy
egimens are used as part of CRT. In the European Society for Med-
cal Oncology (ESMO) NSCLC guideline, two to four cycles of cyclic
osed platinum based doublet chemotherapy are recommended
3]. Platinum is usually combined with etoposide or vinorelbine [3].
n alternative schedule often used in the United States is weekly
arboplatin/paclitaxel [9]. Other concurrent regimens are cyclic
ose platinum/pemetrexed [10], weekly platinum/docetaxel [11]
r daily low dose cisplatin [12].
To our knowledge, there are no phase III head-to-head compar-
sons of these regimens showing an improved OS with a speciﬁc
egimen. A recent retrospective study (N = 1842) compared out-
omes of stage III NSCLC patients treated with cisplatin/etoposide
r carboplatin/paclitaxel concurrent with radiotherapy within the
eterans Health Administration and no signiﬁcant OS differences
ere found [9].
The impact of the speciﬁc chemotherapy regimen used during
RT on the development of symptomatic brain metastases is still
nclear. To answer the question whether there is any inﬂuence of
he CRT chemotherapy regimen used on the development of these
rain metastases, we performed a retrospective multicenter study
n stage III NSCLC treated with CRT.
. Materials and methods
.1. Study subjects
Data of all consecutive stage III NSCLC patients from ﬁve
utch teaching hospitals, treated with deﬁnitive CRT (with/without
urgery) between January 1st 2006 and June 30th 2014 were retro-
pectively analyzed. Exclusion criteria were: diagnosis of another
alignancy within two years of stage III NSCLC (except cervical
ancer in situ, skin cancer, previously diagnosed NSCLC treated
ith curative intent); no 18ﬂuorodeoxyglucose-positron emission
omography (18FDG-PET)-scan; no adequate brain imaging (i.e.
o magnetic resonance imaging (MRI) or contrast-enhanced com-
uted tomography (CE-CT)) during staging; no CRT completion (in
rder to exclude bias from suboptimal treatment); prophylactic
ranial irradiation (PCI) treatment.
The following details were extracted from the medical records:
ge; gender; world health organization performance status (WHO©  2016  Elsevier  Ireland  Ltd.  All rights  reserved.
PS); smoking status; date of pathology diagnosis; staging brain
imaging modality; histology; molecular testing (yes/no, results);
T- and N-stage; TNM stage; cCRT or sCRT; chemotherapy regi-
men; dose radiotherapy (Gy); treatment completion (i.e. all planned
cycles chemotherapy (delay/dose reductions allowed) and radio-
therapy completion); surgery post CRT; date progressive disease
and ﬁrst site of progression (brain only, extracranial only, both);
date symptomatic brain metastases diagnosis, symptoms; whether
regular brain imaging was  performed during follow-up; date of
death/last follow-up. CRT regimens were classiﬁed as daily low
dose cisplatin and cyclic dose doublet chemotherapy. Within the
cyclic dose doublet chemotherapy group, subgroups were made
for taxane and non-taxane based regimens. Patients treated with
sequential cyclic dose doublet chemotherapy followed by radio-
therapy or cCRT were classiﬁed as “cyclic dose” regardless of the
concurrent chemotherapy regimen used. Last date of follow-up was
June 30th, 2015.
The ethics committee of the MUMC+  evaluated the proto-
col (METC 14-5-054) and stated that study approval was not
mandatory according to the Dutch law “Medical Research (human
subjects) Act” [13].
2.2. Statistical analysis
Statistical analysis was performed with SPSS (version 20; SPSS
Inc., Chicago, IL). Patient characteristics were described for the total
group and according to treatment regimen. Signiﬁcant differences
between regimens were assessed by X2-test, Fisher’s exact test,
Mann-Whitney-U test or ANOVA when applicable. Primary end-
points were development of symptomatic brain metastases and
whether the brain was  the only site of ﬁrst relapse, these were
compared with the X2-test. A binary logistic regression model for
brain metastases development was  constructed including covari-
ates that are known risk factors for brain metastases (age, gender,
histology, stage). Chemotherapy regimens (sCRT versus cCRT and
in the cCRT group daily low dose cisplatin versus cyclic dose
regimens) were added to this regression model. Also, subgroup
analyses were performed in the cCRT subgroup for low dose cis-
platin versus non-taxane and taxane based regimens respectively.
For the cCRT subgroup, logistic regression analysis was  also per-
formed for low dose cisplatin versus subgroups of chemotherapy
with ≥50 patients.
Progression free survival (PFS) was  deﬁned as time from stage
III diagnosis till disease progression or death; OS was deﬁned as the
time from stage III diagnosis till death. Patients without event who
were alive at last follow-up or who  were lost-to-follow-up were
censored at last date of follow-up. The Kaplan–Meier method was
used to estimate distribution of survival. Log-rank test was used to
test difference in survival between subgroups. P-values ≤ 0.05 for
two-sided tests were considered statistically signiﬁcant. Distribu-
tion of cumulative incidence of symptomatic brain metastases was
estimated with the competing-risks regression method by Fine and
Gray. For this analysis we used STATA (version 14.0; StataCorp LP,
Texas) as this function is not available in SPSS. Patients without
event who  were alive at last follow-up or who were lost-to-follow-
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ram for study inclusion.
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p were censored at last date of follow-up. Death without brain
etastases was considered a competing event.
. Results
.1. Patient characteristics
Between January 1st 2006 and June 30th 2014, 1026 patients
ere treated with CRT. 188 patients were excluded for the follow-
ng reasons: second primary (N = 32), no adequate baseline brain
maging (N = 81), CRT not completed (N = 66) or PCI (N = 9) (CON-
ORT diagram in Fig. 1).
Hence, 838 patients were eligible: 737 cCRT and 101 sCRT
reated. Patient characteristics for all patients and cCRT/sCRT sub-
roups are shown in Table 1. Characteristics for the cCRT patients
reated with cyclic dose doublet chemotherapy versus daily low
ose cisplatin are depicted in Table 2 (chemotherapy regimens fur-
her speciﬁed in table S1). 87% of the sCRT treated patients received
 cycles of cyclic doublet chemotherapy, the others received 4
ycles. In the cCRT group, 76.9% received 3 cycles of cyclic dose dou-
let chemotherapy (including an optional induction chemotherapy
ycle), the others received 4 cycles except 2 patients who  received
 cycles.
.2. Development of symptomatic brain metastases
153/838 patients (18%) were diagnosed with brain metastases
n the follow-up, of which 143 (93%) were symptomatic. For the
emaining 10, it was not clear whether they had symptoms or not.
he percentage of symptomatic brain metastases diagnosis was
ot signiﬁcantly different for sCRT and cCRT patients 18/101 (18%)
ersus 135/737 (18%, p = 0.904). Cumulative brain metastases inci-
ence is shown in Fig. 2, no signiﬁcant difference was found for sCRT
ersus cCRT treated patients (hazard ratio (HR) (95% CI) 0.93 (0.564-
.539), p = 0.781). In 7/101 (6.9%) and 59/737 (8.0%), respectively,Fig. 2. cumulative incidence of brain metastases for patients treated with concur-
rent  or sequential chemoradiotherapy.
the brain was the only site of ﬁrst relapse, this was  not signiﬁcantly
different (p = 0.707). As compared to patients not developing symp-
tomatic brain metastases, those with metastases were signiﬁcantly
younger (mean age 59 versus 63 years, p < 0.001), had female gen-
der (44% versus 34%, p = 0.018), had adenocarcinoma histology (57%
versus 35%, p < 0.001) and had a more advanced N-stage (93% versus
86%, p = 0.018) (Table 3).
Within the cCRT subgroup, no signiﬁcant differences were
observed between cyclic dose doublet chemotherapy (N = 346)
and daily low dose cisplatin (N = 391). 65/346 (18.8%) and 70/391
(17.9%) patients were diagnosed with symptomatic brain metas-
tases, respectively (p = 0.757). In 25/346 (7.2%) cyclic dose doublet
chemotherapy and 34/391 (8.7%) daily low dose cisplatin patients
respectively, the brain was  the only site of ﬁrst relapse (p = 0.463).
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Table  1
patient characteristics for all eligible patients.
Patient characteristic Total group N = 838 cCRT group N = 737 sCRT group N = 101
Mean age ± SD 62 ± 10 62 ± 10 66 ± 11
(range)  30–84 (30–84) (34–83)
Male  N (%) 535 (64) 468 (64) 67 (66)
WHO  PS N (%)
0–1 779 (93) 691 (94) 88 (87)
2  34 (4) 23 (3) 11 (11)
Missing 25 (3) 23 (3) 2 (2)
Smoking status N (%)
Current 239 (29) 201 (27) 38 (38)
Former 344 (41) 291 (40) 53 (52)
Never  8 (1) 6 (1) 2 (2)
Unknown 247 (29) 239 (32) 8 (8)
Histology N (%)
Adenocarcinoma 324 (39) 283 (38) 41 (41)
Squamous cell carcinoma 281 (33) 237 (32) 44 (44)
Other/NOS 233 (28) 217 (29) 16 (16)
Brain  imaging initial diagnosis N (%)
MRI  720 (86) 635 (86) 85 (84)
CE-CT  118 (14) 102 (14) 16 (16)
Stage  N (%)
IIIA 494 (59) 441 (60) 53 (52)
IIIB  344 (41) 296 (40) 48 (48)
T-stage  N (%)
T0-2 412 (49) 358 (49) 54 (54)
T3-4  426 (51) 379 (51) 47 (47)
N-stage N (%)
N0-1 109 (13) 101 (14) 8 (8)
N2-3  729 (87) 636 (86) 93 (92)
CRT  chemo used N (%)
Cyclic dose 339 (46) 101 (100)
Low  dose cisplatin 398 (54) 0 (0)
Radiotherapy (Gy)
Mean ± SD 65.4 ± 3.4 65.5 ± 3.2 64.6 ± 4.8
Range  45–89.3 45–89.3 45–79.2
Surgery as part of multimodality treatment N (%)
Yes 93 (11) 92 (13) 1 (1)
Type  induction/sequential
Platinum/Gemcitabine 133 (18) 67 (66)
Platinum/Paclitaxel 8 (1) 2 (2)
Platinum/Pemetrexed 41 (6) 23 (23)
Platinum/Etoposide 41 (6) 0 (0)
Cisplatinum/Vinorelbine 3 (0.4) 1 (1)
Unknown 0 (0) 7 (7)
None  508 (69) 0 (0)
Dose  reduction N (%)
Yes 45 (5) 36 (5) 9 (9)
Abbreviations: N: number; cCRT: concurrent chemoradiation; sCRT: sequential chemoradiation; SD: standard deviation; WHO  PS: world health organization performance
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.3. Predictors for symptomatic brain metastases development
In the total group (N = 838), a lower risk of developing symp-
omatic brain metastases was seen in older patients (age as
ontinuous variable, odds ratio (OR) (95% CI) 0.97 (0.95–0.99),
 = 0.002) and squamous carcinoma histology (OR 0.24 (0.14–0.42),
 = 0.001). The chemotherapy regimen used (cCRT versus sCRT)
id not inﬂuence the brain metastases risk (OR 0.88 (0.50–1.57),
 = 0.669). Comparable results were found for the brain as the only
ite of ﬁrst relapse: OR of 0.97 (0.94–0.99, p = 0.006) for increasing
ge, OR 0.26 (0.11–0.61, p = 0.002) for squamous versus adenocarci-
oma histology, OR 0.93 (0.40–2.14, p = 0.855) for cCRT versus sCRT
Table 4).t enhanced computed tomography; T: tumor; N: node; CRT: chemoradiation; Gy:
In the cCRT group (N = 737), a lower risk of developing symp-
tomatic brain metastases was found for older patients (OR 0.98
(0.96–0.99), p = 0.037) and for squamous versus adenocarcinoma
histology (OR 0.19 (0.10–0.36), p < 0.001). For the brain as the only
site of ﬁrst relapse, older patients (OR 0.97 (0.94–1.00), p = 0.034)
and patients with squamous histology (OR 0.25 (0.10–0.64),
p = 0.004) had a lower risk. In none of these subgroup analy-
ses, chemotherapy regimen (daily low dose cisplatin versus cyclic
dose doublet chemotherapy) had an impact on symptomatic brain
metastases development (Table 4). Comparable results were found
for daily low dose cisplatin (N = 391) versus cyclic dose non-taxane
(N = 277) and cyclic dose taxane based regimens (N = 69). There
was also no signiﬁcant difference in brain metastases develop-
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Table 2
patient characteristics for patients treated with concurrent chemo-radiation.
Patient characteristic cyclic dose doublet chemotherapy N = 346 Daily low dose cisplatin N = 391 p-value
Mean age ± SD 62 ± 10 62 ± 10 0.746
(range) 31–84 30–83
Male N (%) 223 (65) 245 (63) 0.646
WHO  PS N (%)a 0.463
0–1  324 (93) 367 (93)
2  9 (3) 14 (4)
Smoking status N (%)a 0.035
Current 125 (37) 76 (49)
Former  213 (62) 78 (50)
Never  4 (1) 2 (1)
Histology N (%) 0.036
Adenocarcinoma 146 (42) 137 (35)
Squamous cell carcinoma 113 (33) 124 (32)
Other/NOS 87 (25) 130 (33)
EGFR mutation N (%)a 0.439
Yes  2 (2) 3 (4)
No  101 (98) 75 (96)
KRAS  mutation N (%)a 0.472
Yes  38 (35) 26 (31)
No  69 (65) 59 (69)
ALK  rearrangement N (%)a 0.919
Yes  3 (12) 4 (13)
No  22 (88) 27 (87)
Brain  imaging initial diagnosis N (%) 0.083
MRI  290 (84) 345 (88)
CE-CT 56 (16) 46 (12)
Stage  N (%) 0.226
IIIA  199 (58) 242 (62)
IIIB  147 (42) 149 (38)
T-stage N (%) 0.941
T0-2  169 (49) 189 (48)
T3-4  177 (51) 202 (52)
N-stage N (%)
N0-1 45 (13) 56 (14) 0.604
N2-3  301 (87) 335 (86)
Type concurrent chemotherapy N (%) N/A
Cisplatin/etoposide 188 (54) –
Carboplatin/etoposide 22 (6) –
Cisplatin/vinorelbin ± cetuximab 65 (19) –
Carboplatin/vinorelbin 4 (1) –
Cisplatin/pemetrexed 6 (2) –
Weekly platinum/docetaxel (± induction cyclic dose chemotherapy) 61 (18) –
Cisplatin low dose daily – 391 (100)
Radiotherapy (Gy) Mean (±SD) 65 (±5) 66 (±1) <0.001
Range  45–89 52–68
Surgery after cCRT N (%) 0.686
Yes  45 (13) 47 (12)
Dose  reduction N (%)
Yes 36 (10) 0 (0) <0.001
Routine brain imaging in follow-up N (%)
Yes 0 (0) 0 (0) –
Abbreviations:  N: number; SD: standard deviation; WHO  PS: world health organization performance status; NOS: not otherwise speciﬁed; EGFR: epidermal growth factor
r e; MR
T on.
m
d
(
p
3
4eceptor; KRAS: Kirsten rat sarcoma viral antigen; ALK: anaplastic lymphoma kinas
:  tumor; N: node; CRT: chemoradiation; Gy: gray; cCRT: concurrent chemoradiati
a computed only for patients with known variables.
ent for the subgroups of cCRT regimens with ≥50 patients:
aily low dose cisplatin (N = 391) versus cisplatin/etoposide
N = 188), cisplatin/vinorelbine ± cetuximab (N = 65), weekly cis-
latin/docetaxel (N = 60) respectively (tables S2 and S3)..4. Progression free survival and overall survival
The median follow-up (95% CI) for patients being alive was
5.1 (42.3–47.8) months. PFS (95% CI) was 16.7 (14.1–19.4) monthsI: magnetic resonance imaging; CE-CT: contrast enhanced computed tomography;
for cCRT and 13.3 (10.9–15.7) months for sCRT (hazard ratio (HR)
0.82 (0.64–1.06, p = 0.122). The OS was  24.5 (21.9–27.2) and 16.8
(13.7–19.8) months, respectively (HR 0.76 (0.59–0.98), p = 0.034).
One-year survival was 70% and 66%, respectively (p = 0.451). For
daily low dose cisplatin cCRT, PFS was 15.1 (11.0–19.3) months
compared to 17.2 (14.0–20.3) months for cyclic dose cCRT (HR 1.11
(0.92–1.33), p = 0.270). OS was  23.7 (19.9–27.5) months for daily
low dose cisplatin cCRT and 25.5 (21.9–29.0) months for cyclic
L.E.L. Hendriks et al. / Lung Cancer 101 (2016) 68–75 73
Table  3
patient characteristics for patients developing symptomatic brain metastases, compared to those without symptomatic brain metastases.
Patient characteristic Brain metastases N = 153 No brain metastases N = 685 p-value
Mean age ± SD 59 ± 9 63 ± 10 <0.001
(range) 36–80 30–84
Male N (%) 85 (56) 450 (66) 0.018
WHO  PS N (%)a
0–1 141 (98) 638 (95) 0.165
2  3 (2) 31 (5)
Smoking status N (%)a
Current 51 (46) 188 (39) 0.400
Former 59 (53) 285 (59)
Never 1 (1) 7 (1)
Histology N (%)
Adenocarcinoma 87 (57) 237 (35) <0.001
Squamous cell carcinoma 19 (12) 262 (38)
Other/NOS 47 (31) 186 (27)
EGFR  mutation N (%)a
Yes 3 (5) 3 (2) 0.357
No  57 (95) 146 (98)
KRAS  mutation N (%)a
Yes 28 (40) 47 (31) 0.173
No  42 (60) 106 (69)
ALK rearrangement N (%)a
Yes 2 (10) 5 (12) 0.825
No  18 (90) 37 (88)
Brain  imaging initial diagnosis N (%)
MRI  130 (85) 590 (86) 0.708
CE-CT  23 (15) 95 (14)
Stage  N (%)
IIIA 86 (56) 408 (60) 0.446
IIIB  67 (44) 277 (40)
T-stage N (%)
T0-2 78 (51) 334 (49) 0.619
T3-4  75 (49) 351 (51)
N-stage N (%)
N0-1 11 (7) 98 (14) 0.018
N2-3  142 (93) 587 (86)
Radiotherapy (Gy)
Mean ± SD 65 ± 3 65 ± 4 0.875
Range 45–79 45–89
Surgery after cCRT N (%)
Yes 20 (13) 73 (11) 0.390
Dose  reduction N (%)
Yes 5 (3) 40 (6) 0.319
Abbreviation;: N: number; SD: standard deviation; WHO  PS: world health organization performance status; NOS: not otherwise speciﬁed; EGFR: epidermal growth factor
r e; MR
T n.
d
s
4
t
t
i
I
w
m
a
w
h
seceptor; KRAS: Kirsten rat sarcoma viral antigen; ALK: anaplastic lymphoma kinas
:  tumor; N: node; CRT: chemoradiation; Gy: gray; cCRT: concurrent chemoradiatio
a computed only for patients with known data.
ose cCRT, respectively (HR 1.08 (0.90–1.30, p = 0.397). One-year
urvival was 68% and 73%, respectively (p = 0.116).
. Discussion
The brain is a frequent site of symptomatic relapse after CRT and
his has a negative impact on QoL and OS [4–7]. In this retrospec-
ive multicenter study the type of chemotherapy did not have an
mpact on the incidence of symptomatic brain metastases in stage
II NSCLC patients treated with CRT. Also, no signiﬁcant differences
ere found for sCRT versus cCRT treated patients. Although brain
etastases before treatment start were excluded by brain MRI/CTnd all patients were 18FDG-PET-CT staged, still 18% of patients
ere diagnosed with symptomatic brain metastases, and for almost
alf of them the brain was the only site of ﬁrst relapse. As demon-
trated in previous studies, adenocarcinoma histology and youngerI: magnetic resonance imaging; CE-CT: contrast enhanced computed tomography;
age were signiﬁcant predictors for brain metastases development
[4,8].
An explanation for our ﬁndings is that subclinical brain
metastases are already present at staging and that the type of
chemotherapy regimens does not differ in the effect to eradicate
these tumor deposits. This is likely due to the fact that these
chemotherapies have almost no penetration through an intact
blood-brain barrier and/or are substrates for brain efﬂux pumps
[14]. In general, chemotherapy added to local radical treatment
improves OS, as was  found in a recent meta-analysis (HR 0.88
(p = 0.0009), 4% increase in 5-year survival) [15]. Impact on brain
metastases development was  not evaluated. To evaluate whether
the lack of impact of the chemotherapy regimen on symptomatic
brain metastases was speciﬁc to the brain we performed the same
analyses for extracranial relapses. No signiﬁcant differences were
found for sCRT versus cCRT treated patients. Also, no differences
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Table 4
Multivariate logistic regression analysis for symptomatic brain metastases
development.
All chemoradiation patients (N = 838)
Brain relapse pattern OR (95% CI) p-value
All brain relapses
Gender (female vs male) 1.05 (0.72–1.53) 0.807
Age  (continuous, older vs younger) 0.97 (0.95–0.99) 0.002
T-stage (T3-4 vs T0-2) 1.19 (0.81–1.74) 0.375
N-stage (N2-3 vs N0-1) 1.80 (0.89–3.64) 0.102
Treatment regimen (concurrent vs
sequential)
0.88 (0.50–1.57) 0.669
Histology (squamous vs
adenocarcinoma)
0.24 (0.14–0.42) <0.001
Histology (NOS vs adenocarcinoma) 0.75 (0.50–1.14) 0.174
Brain as the only site of ﬁrst relapse
Gender (female vs male) 1.15 (0.68–1.95) 0.613
Age  (continuous, older vs younger) 0.97 (0.94–0.99) 0.006
T-stage (T3-4 vs T0-2) 1.24 (0.71–2.14) 0.449
N-stage (N2-3 vs N0-1) 0.93 (0.40–2.18) 0.866
Treatment regimen (concurrent vs
sequential)
0.93 (0.40–2.14) 0.855
Histology (squamous vs
adenocarcinoma)
0.26 (0.11–0.61) 0.002
Histology (NOS vs adenocarcinoma) 0.99 (0.56–1.75) 0.981
Only  concurrent chemoradiation patients (N = 737)
Brain relapse pattern OR (95% CI) p-value
All brain relapses
Gender (female vs male) 1.01 (0.67–1.51) 0.974
Age  (continuous, older vs younger) 0.98 (0.96–0.99) 0.037
T-stage (T3-4 vs T0-2) 1.18 (0.78–1.77) 0.431
N-stage (N2-3 vs N0-1) 1.88 (0.90–3.93) 0.095
Treatment regimen (low dose
cisplatin vs cyclic dose)
0.96 (0.65–1.41) 0.819
Histology (squamous vs
adenocarcinoma)
0.19 (0.10–0.36) <0.001
Histology (NOS vs adenocarcinoma) 0.73 (0.47–1.12) 0.153
Brain as the only site of ﬁrst relapse
Gender (female vs male) 1.21 (0.69–2.12) 0.497
Age  (continuous, older vs younger) 0.97 (0.94–1.00) 0.034
T-stage (T3-4 vs T0-2) 1.25 (0.70–2.24) 0.453
N-stage (N2-3 vs N0-1) 0.89 (0.37–2.11) 0.787
Treatment regimen (low dose
cisplatin vs cyclic dose)
1.21 (0.70–2.09) 0.498
Histology (squamous vs
adenocarcinoma)
0.25 (0.10–0.64) 0.004
Histology (NOS vs adenocarcinoma) 1.00 (0.55–1.80) 0.995
Abbreviations:  N: number; OR: odds ratio; CI: conﬁdence interval; T: tumor; N: node;
NOS: not otherwise speciﬁed.
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III NSCLC has no impact on the subsequent development of clini-
cally manifest brain metastases. It remains important to identifyold values are the signiﬁcant values.
ere found for the speciﬁc chemotherapy regimens used in a cCRT
egimen (data not shown). The ﬁnding that the chemotherapy
egime does not inﬂuence brain metastases incidence is not entirely
ew. For example, the early RTOG 88-08/ECOG 4588 trial random-
zing 490 stage III NSCLC patients between radical radiotherapy
standard or hyperfractionated) and sCRT revealed no difference
n brain metastases incidence in the follow up (but signiﬁcantly
ess distant metastases other than brain for sCRT compared to the
adiotherapy alone arms (p = 0.04)) [16]. However, it is likely that
ue to inadequate brain imaging metastases at initial staging were
issed. Indeed, in a recent study using brain MRI  up to 16% had
symptomatic metastases at initial staging [5].
Strong points of this study are that it is a multi-center study
ncluding over 800 consecutive stage III NSCLC patients, all with up-
o-date staging and all treated with CRT, which represents current
ractice. In order to exclude bias from suboptimal treatment only
atients who completed treatment were included.ncer 101 (2016) 68–75
Limitations of our study are that within the cyclic dose dou-
blet chemotherapy group different chemotherapy regimens were
used, and that the number of patients per cyclic dose regimen
was relatively small for comparing these regimens. However, when
we compared the major subgroups of chemotherapy within the
cCRT group no differences were found regarding symptomatic
brain metastases development. Comparable results were found
for daily low dose cisplatin versus cyclic dose taxane and non-
taxane based regimens, respectively. Some patients did receive
weekly platinum/docetaxel concurrent with radiotherapy (often
preceded by full dose platinum based doubled chemotherapy) and
these patients were grouped within the cyclic dose group. One can
argue that this regimen has some low dose components. When we
excluded these patients from our analyses, results did not change
signiﬁcantly (data not shown). In the present study we  did not
restrict development of symptomatic brain metastases to a cer-
tain time point after diagnosis of stage III NSCLC. One can argue
that it is especially important to prevent development of symp-
tomatic brain metastases in the ﬁrst year after stage III diagnosis,
as these patients did not have beneﬁt from their intensive CRT treat-
ment. However, results remained comparable when we restricted
our analyses to development of brain metastases within one year of
stage III NSCLC diagnosis (results not shown). Adenocarcinoma his-
tology is a risk factor for brain metastases and it is possible that the
chemotherapeutic regimens used have a different impact on ade-
nocarcinoma histology compared to other histologies. When the
analyses above were repeated with only adenocarcinoma patients,
results did not change signiﬁcantly (data not shown). Furthermore,
it is a retrospective study and as such follow up was not stan-
dardized but according to local practice (i.e. PFS data difﬁcult to
compare). Only patients who completed their CRT treatment were
included (no intention-to-treat-analysis) and patient selection for
CRT eligibility was according to local protocols. This may  have
caused an imbalance in favor of the patients treated with sCRT
regarding prognosis in the different subgroups. It is not common
practice nor advised in guidelines to perform regular brain imag-
ing in the follow-up of radically treated stage III NSCLC patients [3].
This results in underdiagnosis of asymptomatic brain metastases.
One can argue the relevance of asymptomatic metastases when
a patient dies of extracranial disease. Furthermore, bias regarding
different regimes for cerebral metastases screening did not occur
because brain imaging was  only performed when a patient had
symptoms indicative for brain metastases or when brain imaging
was required for renewed staging. As it is not common practice to
perform molecular screening in stage III NSCLC, molecular char-
acteristics were mostly unknown. However, as especially patients
with an ALK-rearrangement are prone to develop brain metastases
and percentage of ALK-rearranged patients is low in the literature
(±5%) it is unlikely that this has caused any bias [17]. Treatment
factors that can reduce brain metastases development are impor-
tant to identify, for these metastases are often associated with
reduced QoL and poor prognosis [6,7]. Prophylactic cranial irradi-
ation (PCI) to eradicate microscopic brain metastases is a possible
treatment option. PCI is currently evaluated in the phase III ran-
domized NVALT11/DLCRG 02 study (NCT01282437). It is closed for
accrual and results are awaited.
5. Conclusion
The speciﬁc chemotherapy regimen used during CRT for stagemodiﬁable factors in order to reduce the development of brain
metastases.
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